Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis

doi:10.12998/wjcc.v7.i5.600

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8022)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-2) series.

Item

Count

PDF

402

WORD

263

HTML

3887

Figures (1-8)

162

Tables (1-2)

152

Sum=4866

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

513

Download

535

Sum=1048

Publishing Process of This Article

Item

Count

Browse

861

Download

1247

Sum=2108

Mar 6, 2019 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Cases. Mar 6, 2019; 7(5): 600-615
Published online Mar 6, 2019. doi: 10.12998/wjcc.v7.i5.600

Full Size Figure Download Figure

Figure 6 Forest plots of risk ratios of grade 3-4 adverse effects associated with docetaxel, cisplatin, and 5-fluorouracil vs epirubicin, cisplatin, and 5-fluorouracil. ECF: Epirubicin, cisplatin, and 5-fluorouracil; DCF: Docetaxel, cisplatin, and 5-fluorouracil.

Citation: Li B, Chen L, Luo HL, Yi FM, Wei YP, Zhang WX. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis. World J Clin Cases 2019; 7(5): 600-615
URL: https://www.wjgnet.com/2307-8960/full/v7/i5/600.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i5.600